Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Xu, Miao  [Clear All Filters]
Journal Article
Huang W, Cheng Y-S, Yang S, Swaroop M, Xu M, Huang W, Zheng W. Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells. Exp Cell Res. 2021:112785.
Xu X, Pradhan M, Xu M, Cheng Y-S, Beers J, Linask KL, Lin Y, Zheng W, Zou J. Four induced pluripotent stem cell lines (TRNDi021-C, TRNDi023-D, TRNDi024-D and TRNDi025-A) generated from fibroblasts of four healthy individuals. Stem Cell Res. 2020;49:102011.
Li R, Pradhan M, Xu M, Baskfield A, Farkhondeh A, Cheng Y-S, Beers J, Zou J, Liu C, Might M, et al. Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene. Stem Cell Res. 2018;34:101362.
Hong J, Xu M, Li R, Cheng Y-S, Kouznetsova J, Beers J, Liu C, Zou J, Zheng W. Generation of an induced pluripotent stem cell line (TRNDi008-A) from a Hunter syndrome patient carrying a hemizygous 208insC mutation in the IDS gene. Stem Cell Res. 2019;37:101451.
Pavlinov I, Farkhondeh A, Yang S, Xu M, Cheng Y-S, Beers J, Zou J, Liu C, Might M, Rodems S, et al. Generation of two gene corrected human isogenic iPSC lines (NCATS-CL6104 and NCATS-CL6105) from a patient line (NCATS-CL6103) carrying a homozygous p.R401X mutation in the NGLY1 gene using CRISPR/Cas9. Stem Cell Res. 2021;56:102554.
Pradhan M, Farkhondeh A, Cheng Y-S, Xu M, Beers J, Zou J, Liu C, Might M, Rodems S, Baumgärtel K, et al. An induced pluripotent stem cell line (NCATS-CL9075) from a patient carrying compound heterozygote mutations, p.R390P and p.L318P, in the NGLY1 gene. Stem Cell Res. 2021;54:102400.
Huang W, Xu M, Li R, Baskfield A, Kouznetsova J, Beers J, Zou J, Liu C, Zheng W. An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene. Stem Cell Res. 2019;37:101427.
Ma J, Ning Y-N, Xu M, Hou Y, Wang N, Hou X-Y, Yu Y-Y, Li H, He W-D, Shao L-L, et al. Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia. Blood. 2013.